Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anwaar Saeed

Showing results (151-160 of 167) with videos related to

Pageof 17
Sort By:
Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
Cancer Letters|June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort studyKylie Fletcher, Alessio Cortellini, Teja Ganta, et al.
JHEP Reports : Innovation in Hepatology|January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumabMeng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2026
Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE ScoreLorenzo Canova, Eleonora Alimenti, Lorenzo Argiento, et al.
Cancers|January 11, 2022
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular CarcinomaAmbreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practiceDavid J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Journal of Hepatocellular Carcinoma|April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and BevacizumabBernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
JHEP Reports : Innovation in Hepatology|January 26, 2024
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinomaLorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Pageof 17

Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
Cancer Letters|June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort studyKylie Fletcher, Alessio Cortellini, Teja Ganta, et al.
JHEP Reports : Innovation in Hepatology|January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumabMeng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2026
Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE ScoreLorenzo Canova, Eleonora Alimenti, Lorenzo Argiento, et al.
Cancers|January 11, 2022
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular CarcinomaAmbreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practiceDavid J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Journal of Hepatocellular Carcinoma|April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and BevacizumabBernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
JHEP Reports : Innovation in Hepatology|January 26, 2024
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinomaLorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Pageof 17